The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

Journal of Immunology

Volumn 182, Issue 10, 2009, Pages 6435-6443

  Lindqvist, Madelene ^a   Persson, Josefine ^a   Thörn, Karolina ^a   Harandi, Ali M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN D; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MEDROXYPROGESTERONE ACETATE; MYELOID DIFFERENTIATION FACTOR 88; SAPONIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MEDIASTINUM LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIGENS, CD1D; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; LYMPHOID TISSUE; MICE; MICE, KNOCKOUT; VIRAL ENVELOPE PROTEINS;

EID: 69249112615     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900136     Document Type: Article

References (30)

1. Whitley, R. J. 2002. Herpes simplex virus infection. Semin. Pediatr. Infect. Dis. 13: 6-11.
2. Abu-Raddad, L. J., A. S. Magaret, C. Celum, A. Wald, I. M. Longini, Jr., S. G. Self, and L. Corey. 2008. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3: e2230.
3. de Bruyn, G., M. Vargas-Cortez, T. Warren, S. K. Tyring, K. H. Fife, J. Lalezari, R. C. Brady, M. Shahmanesh, G. Kinghorn, K. R. Beutner, et al. 2006. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24: 914-920.
4. Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials: Chiron HSV Vaccine Study Group. J. Am. Med. Assoc. 282: 331-340. (Pubitemid 29350487)
5. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347: 1652-1661. (Pubitemid 35340783)
6. Gallichan, W. S., R. N. Woolstencroft, T. Guarasci, M. J. McCluskie, H. L. Davis, and K. L. Rosenthal. 2001. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166: 3451-3457.
7. Harandi, A. M., K. Eriksson, and J. Holmgren. 2003. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77: 953-962.
8. Tengvall, S., and A. M. Harandi. 2008. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice. J. Reprod. Immunol. 78: 49-57. (Pubitemid 351609116)
9. Tengvall, S., D. O'Hagan, and A. M. Harandi. 2008. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Antiviral Res. 78: 202-214.
10. Gavin, A. L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee. 2006. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314: 1936-1938.
11. + NK T lymphocytes. J. Immunol. 161: 3271-3281.
12. Giaccone, G., C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. von Blomberg, R. J. Scheper, H. J. van der Vliet, A. J. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8: 3702-3709. (Pubitemid 35424759)
13. Gonzalez-Aseguinolaza, G., L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624. (Pubitemid 34461506)
14. Ishikawa, A., S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa. 2005. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11: 1910-1917. (Pubitemid 40471857)
15. Ko, S. Y., H. J. Ko, W. S. Chang, S. H. Park, M. N. Kweon, and C. Y. Kang. 2005. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175: 3309-3317.
16. Ashkar, A. A., and K. L. Rosenthal. 2003. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J. Virol. 77: 10168-10171.
17. Grubor-Bauk, B., A. Simmons, G. Mayrhofer, and P. G. Speck. 2003. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα14-Jα281 TCR. J. Immunol. 170: 1430-1434. (Pubitemid 36139511)
18. Yuan, W., A. Dasgupta, and P. Cresswell. 2006. Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling. Nat. Immunol. 7: 835-842. (Pubitemid 44084090)
19. - DC initiate antigen presentation following intranasal coadministration of α-GalCer. Eur. J. Immunol. 37: 2127-2137.
20. Ashkar, A. A., S. Bauer, W. J. Mitchell, J. Vieira, and K. L. Rosenthal. 2003. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77: 8948-8956.
21. Tengvall, S., A. Lundqvist, R. J. Eisenberg, G. H. Cohen, and A. M. Harandi. 2006. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80: 5283-5291. (Pubitemid 43752773)
22. Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198: 267-279. (Pubitemid 36987852)
23. Harandi, A. M., B. Svennerholm, J. Holmgren, and K. Eriksson. 2001. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired γ interferon-mediated protective immunity. J. Virol. 75: 6705-6709.
24. + T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82: 845-853.
25. Milligan, G. N., and D. I. Bernstein. 1997. Interferon-γ enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229: 259-268.
26. Parr, M. B., and E. L. Parr. 1999. The role of γ interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Virology 258: 282-294. (Pubitemid 29390237)
27. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150. (Pubitemid 28361303)
28. Malmgaard, L., J. Melchjorsen, A. G. Bowie, S. C. Mogensen, and S. R. Paludan. 2004. Viral activation of macrophages through TLR-dependent and -independent pathways. J. Immunol. 173: 6890-6898. (Pubitemid 39541076)
29. Mestecky, J., Z. Moldoveanu, and M. W. Russell. 2005. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am. J. Reprod. Immunol. 53: 208-214. (Pubitemid 40542802)
30. Kawana, K., J. Matsumoto, S. Miura, L. Shen, Y. Kawana, T. Nagamatsu, T. Yasugi, T. Fujii, H. Yang, A. J. Quayle, et al. 2008. Expression of CD1d and ligand-induced cytokine production are tissue specific in mucosal epithelia of the human lower reproductive tract. Infect. Immun. 76: 3011-3018.